The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.

Antiviral Agents / chemistry Cysteine Endopeptidases / chemistry Humans Ligands Peptide Hydrolases Peptidomimetics / chemistry Protease Inhibitors / chemistry SARS-CoV-2 COVID-19 Drug Treatment
3C Like protease Peptidomimetic inhibitors SARS-CoV-2

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Aug 2022
Historique:
received: 24 03 2022
revised: 29 04 2022
accepted: 09 05 2022
pubmed: 1 6 2022
medline: 24 6 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), as the pathogen of coronavirus disease 2019 (COVID-19), has infected millions of people and took hundreds of thousands of lives. Unfortunately, there is deficiency of effective medicines to prevent or treat COVID-19. 3C like protease (3CL

Identifiants

DOI: 10.1016/j.ejmech.2022.114458 PMID: 35635946 PMC: PMC9098890
pubmed: 35635946
pii: S0223-5234(22)00360-9
doi: 10.1016/j.ejmech.2022.114458
pmc: PMC9098890
pii:
doi:

Substances chimiques

Antiviral Agents 0
Ligands 0
Peptidomimetics 0
Protease Inhibitors 0
Peptide Hydrolases EC 3.4.-
Cysteine Endopeptidases EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114458

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Références

Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
Antiviral Res. 2020 Jul;179:104811
pubmed: 32360182
J Med Chem. 2020 Nov 12;63(21):12725-12747
pubmed: 33054210
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
J Biol Chem. 2005 Sep 2;280(35):31257-66
pubmed: 15788388
Nat Commun. 2020 Aug 27;11(1):4282
pubmed: 32855413
Eur J Med Chem. 2016 Nov 29;124:559-573
pubmed: 27614190
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Med Chem. 2015 Dec 10;58(23):9414-20
pubmed: 26571192
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Eur J Med Chem. 2021 Oct 15;222:113584
pubmed: 34118724
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377
pubmed: 32738988
Expert Opin Ther Pat. 2010 Jan;20(1):59-71
pubmed: 20021285
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
J Med Chem. 2019 Jul 11;62(13):6146-6162
pubmed: 31184893
J Med Chem. 2016 Jul 28;59(14):6595-628
pubmed: 26878082
J Med Chem. 2018 Nov 21;61(22):10333-10339
pubmed: 30365311
ACS Catal. 2020;10:5871-5890
pubmed: 32391184

Auteurs

Hao Wang (H)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China.

Rongjuan Pei (R)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Xin Li (X)

College of Life Science, Nankai University, Tianjin, 300353, People's Republic of China.

Weilong Deng (W)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China.

Shuai Xing (S)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China.

Yanan Zhang (Y)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Chen Zhang (C)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China.

Shuai He (S)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China.

Hao Sun (H)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Shuqi Xiao (S)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Jin Xiong (J)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Yecheng Zhang (Y)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Xinwen Chen (X)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China.

Yaxin Wang (Y)

School of Life Science, Tianjin University, Tianjin, 300110, People's Republic of China.

Yu Guo (Y)

College of Life Science, Nankai University, Tianjin, 300353, People's Republic of China. Electronic address: guoyu@nankai.edu.cn.

Bo Zhang (B)

Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, People's Republic of China. Electronic address: zhangbo@wh.iov.cn.

Luqing Shang (L)

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, KLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, 300353, People's Republic of China. Electronic address: shanglq@nankai.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › The structure-based design of peptidomimetic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Endopeptidases › Cysteine endopeptidases › The structure-based design of peptidomimetic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The structure-based design of peptidomimetic...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › The structure-based design of peptidomimetic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › The structure-based design of peptidomimetic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Peptidomimétiques › The structure-based design of peptidomimetic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéases › The structure-based design of peptidomimetic...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › The structure-based design of peptidomimetic...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitements médicamenteux de la COVID-19 › The structure-based design of peptidomimetic...